Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (IPHA) announced significant progress in its clinical pipeline, highlighted by the first patient dosed in AstraZeneca's Phase 3 clinical trial, PACIFIC-9, triggering a $50 million milestone payment. This will enhance the company's cash position to €131.7 million as of March 31, 2022. Revenue for Q1 2022 was €2.6 million, down from €4.5 million year-over-year, primarily from collaboration agreements. The company is optimistic about future clinical milestones and updates on its diverse pipeline of immuno-oncology treatments.

On May 1, 2022, Innate Pharma reported its outstanding shares and voting rights per French market regulations. The company has a total of 79,753,657 ordinary shares and 6,514 Preferred Shares 2016, along with 7,581 Preferred Shares 2017. The total theoretical voting rights amount to 80,511,497, while the exercisable voting rights stand at 80,492,922. These figures ensure transparency in shareholding and align with AMF regulations. Innate Pharma is focused on oncology, leveraging its expertise in therapeutic antibodies.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has filed a prospectus supplement with the SEC for an At-The-Market (ATM) program to offer and sell up to $75 million in American Depositary Shares (ADS). The proceeds will support R&D and general corporate purposes. The company plans to issue up to 23,673,831 ADSs, potentially diluting shareholder value by approximately 26%. Qualified institutional buyers and accredited investors will be eligible for purchase. The program's effectiveness depends on market conditions and may be updated quarterly on the company’s website.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call on May 10, 2022, at 2 p.m. CEST to discuss its business progress in Q1 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Participants can join via webcast or telephone. Innate Pharma is dedicated to oncology innovations through therapeutic antibodies, aiming to enhance treatment outcomes for cancer patients. They have significant collaborations with top biotech firms, strengthening their pipeline against high unmet medical needs.

Innate Pharma announced the first patient dosing in the Phase 3 PACIFIC-9 trial for patients with unresectable Stage III non-small cell lung cancer (NSCLC). This trial evaluates the efficacy of durvalumab in combination with monalizumab or oleclumab. The initiation of the trial triggers a $50 million milestone payment from AstraZeneca to Innate, strengthening its cash position. The PACIFIC-9 study aims to assess whether these combinations improve treatment outcomes following standard platinum-based concurrent chemoradiation therapy.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host its Annual General Meeting (AGM) on May 20, 2022, at 10:30 a.m. CEST in Marseille, France. The AGM will be broadcasted live, and only registered shareholders can participate. Shareholders must register their shares at least two business days before the AGM. The Notice of Meeting published on April 8, 2022, includes the agenda and proposed resolutions. Documentation for the AGM is available on the Company’s website.

Innate Pharma announced the filing of its 2021 Universal Registration Document with the French market authority AMF and its annual report on Form 20-F with the SEC. Both filings cover the year ending December 31, 2021, and are accessible via the company's and regulatory websites. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment, supported by partnerships with major biopharmaceutical companies. The company is based in Marseille, France, and trades on Euronext Paris and Nasdaq under the ticker IPHA.

Innate Pharma reported a net loss of €52.8 million for 2021, showing an improvement from a €64.0 million loss in 2020. Revenue dropped 64.6% to €24.7 million, largely due to reduced collaboration revenue from AstraZeneca. The cash position stands at €159.7 million. Notable advancements include the initiation of a Phase 3 trial for monalizumab with AstraZeneca and promising data from the lacutamab study in mycosis fungoides. The company also highlighted progress in its ANKET platform with Sanofi's Phase 1 trial initiation. A conference call is scheduled for today to discuss these results.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call set for March 24, 2022, at 2 p.m. CET to discuss its financial results for the full year ending December 31, 2021. Key executives, including the CEO and CFO, will participate in the call. The event will be accessible via a live webcast and phone dial-in options. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system against cancer and maintains collaborations with major biopharmaceutical companies like AstraZeneca and Bristol-Myers Squibb.